LONDON — The German biotech Tubulis, which is designing a series of next-generation chemotherapy treatments, said Wednesday it had raised a $358 million Series C, a sizable funding round that will help it push its lead drug candidate into trials in additional types of cancer.

Tubulis, based in Munich, is developing a suite of what are known as antibody-drug conjugates , medicines that are designed to deliver chemo directly to tumor sites, unleashing the toxic therapy on cancer cells while avoiding the whole-body side effects that come with traditional chemotherapy.

The company’s most advanced product, known as TUB-040, is being tested in types of ovarian and non-small cell lung cancer. Tubulis said the influx of money will allow it to test the molecule in earlier lines of treatment and

See Full Page